• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

    3/16/26 4:57:00 PM ET
    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ALC alert in real time by email

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement.

    "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by delivering technologies that improve efficiency for surgeons and outcomes for patients," said David J. Endicott, Chief Executive Officer of Alcon.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

    Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260316607144/en/

    Investor Relations

    Daniel Cravens, Allen Trang

    + 41 589 112 110 (Geneva)

    + 1 817 615 2789 (Fort Worth)

    [email protected]

    Media Relations

    Steven Smith

    + 41 589 112 111 (Geneva)

    + 1 817 551 8057 (Fort Worth)

    [email protected]

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC
    $LNSR

    CompanyDatePrice TargetRatingAnalyst
    Alcon Inc.
    $ALC
    2/26/2026$97.00Equal Weight → Overweight
    Wells Fargo
    Alcon Inc.
    $ALC
    1/30/2026Mkt Perform
    William Blair
    Alcon Inc.
    $ALC
    1/20/2026Hold → Buy
    Deutsche Bank
    Alcon Inc.
    $ALC
    1/9/2026Buy → Hold
    Stifel
    Alcon Inc.
    $ALC
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    Alcon Inc.
    $ALC
    8/21/2025Overweight → Neutral
    Analyst
    Alcon Inc.
    $ALC
    5/20/2025Buy → Hold
    Deutsche Bank
    Alcon Inc.
    $ALC
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    More analyst ratings

    $ALC
    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d

    3/16/26 4:57:00 PM ET
    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

    ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unli

    3/16/26 4:30:00 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Alcon Surpasses 175 Million IOLs Implanted Globally

    Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom from glasses; Vivity has a proven exceptionally low rate of visual disturbances2-8,**,Δ,§,^,‡ Alcon is committed to furthering innovation in the IOL space and plans to launch new technologies in key markets this year Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been implanted worldwide.9,+ Alcon has more than 30 years of IOL experience with its robust portfolio

    3/2/26 8:03:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $ALC
    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,392 shares, decreasing direct ownership by 0.67% to 357,069 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    2/20/26 4:30:20 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,076 shares, decreasing direct ownership by 0.63% to 170,459 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    2/20/26 4:30:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    2/20/26 4:30:07 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $ALC
    $LNSR
    SEC Filings

    View All

    Amendment: LENSAR Inc. filed SEC Form 8-K: Other Events

    8-K/A - LENSAR, Inc. (0001320350) (Filer)

    3/13/26 6:02:01 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Other Events

    8-K - LENSAR, Inc. (0001320350) (Filer)

    3/12/26 4:17:34 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - LENSAR, Inc. (0001320350) (Filer)

    2/25/26 5:09:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $ALC
    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00

    2/26/26 7:10:22 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon upgraded by Deutsche Bank

    Deutsche Bank upgraded Alcon from Hold to Buy

    1/20/26 8:36:02 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $ALC
    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $ALC
    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

    ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unli

    3/16/26 4:30:00 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales

    Fourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated $2.3 billion of cash from operations and $1.7 billion of free cash flow3 in full-year 2025 Returned $848 million to shareholders through share repurchases and dividends Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant curren

    2/24/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care